MX2018002507A - Metodo para la inhibicion de la absorcion de lipidos y/o la promocion de excrecion de lipidos usando d-psicosa. - Google Patents
Metodo para la inhibicion de la absorcion de lipidos y/o la promocion de excrecion de lipidos usando d-psicosa.Info
- Publication number
- MX2018002507A MX2018002507A MX2018002507A MX2018002507A MX2018002507A MX 2018002507 A MX2018002507 A MX 2018002507A MX 2018002507 A MX2018002507 A MX 2018002507A MX 2018002507 A MX2018002507 A MX 2018002507A MX 2018002507 A MX2018002507 A MX 2018002507A
- Authority
- MX
- Mexico
- Prior art keywords
- psychosa
- lipids
- body fat
- lipid
- psicose
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 7
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 title 1
- 230000029142 excretion Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 210000000577 adipose tissue Anatomy 0.000 abstract 3
- 230000037396 body weight Effects 0.000 abstract 2
- 235000013376 functional food Nutrition 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 210000003608 fece Anatomy 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
La presente invención se relaciona con una composición para la prevención o tratamiento de enfermedades metabólicas relacionadas con lípidos. La composición de acuerdo con la presente invención comprende D-psicosa como ingrediente activo. La D-psicosa tiene la capacidad de inhibir la absorción de lípidos en el intestino delgado y aumentar considerablemente los niveles de lípidos en las heces. Debido a su capacidad, la D-psicosa es efectiva para inhibir la formación de grasa corporal. Además, la D-psicosa reduce el peso corporal, la masa de grasa corporal y los lípidos plasmáticos a niveles normales para normalizar el peso corporal, la masa de grasa corporal y los perfiles de lípidos en plasma. Debido a estas ventajas, se espera que la D-psicosa encuentre aplicación en medicamentos farmacéuticos, alimentos funcionales para la salud y alimentos funcionales adecuados para la prevención y/o tratamiento de enfermedades metabólicas relacionadas con los lípidos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150123437A KR101692033B1 (ko) | 2015-09-01 | 2015-09-01 | Ｄ-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
| PCT/KR2016/009812 WO2017039365A1 (ko) | 2015-09-01 | 2016-09-01 | Ｄ-싸이코스를 이용한 지질 흡수 억제 및/또는 배출 촉진 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018002507A true MX2018002507A (es) | 2018-06-11 |
Family
ID=57797262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002507A MX2018002507A (es) | 2015-09-01 | 2016-09-01 | Metodo para la inhibicion de la absorcion de lipidos y/o la promocion de excrecion de lipidos usando d-psicosa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20180243325A1 (es) |
| EP (1) | EP3345608B1 (es) |
| JP (1) | JP6619882B2 (es) |
| KR (1) | KR101692033B1 (es) |
| CN (1) | CN107921052A (es) |
| BR (1) | BR112018003842A2 (es) |
| CA (1) | CA2996872A1 (es) |
| CL (1) | CL2018000523A1 (es) |
| CO (1) | CO2018002394A2 (es) |
| MX (1) | MX2018002507A (es) |
| RU (1) | RU2725145C2 (es) |
| UA (1) | UA122342C2 (es) |
| WO (1) | WO2017039365A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7031825B2 (ja) * | 2016-10-06 | 2022-03-08 | シージェイ チェイルジェダン コーポレーション | 保存安定性が改善されたトマトケチャップ |
| JP6919969B2 (ja) | 2016-10-07 | 2021-08-18 | シージェイ チェイルジェダン コーポレーションＣｊ Ｃｈｅｉｌｊｅｄａｎｇ Ｃｏｒｐｏｒａｔｉｏｎ | アルロースおよび塩を含む味質の改善された甘味料組成物および塩を用いたアルロースの味質改善方法 |
| KR102004914B1 (ko) | 2016-10-10 | 2019-07-30 | 씨제이제일제당 (주) | 알룰로스를 포함하는 식물 담금청 및 이의 제조방법 |
| SG11201903372WA (en) | 2016-12-21 | 2019-05-30 | Cj Cheiljedang Corp | Amino acid beverage containing allulose |
| KR20180075423A (ko) * | 2016-12-26 | 2018-07-04 | 씨제이제일제당 (주) | 알룰로스를 포함하는, 식물성 유지의 생체 외 배출 촉진용 조성물 |
| JP6948671B2 (ja) * | 2017-06-29 | 2021-10-13 | 松谷化学工業株式会社 | Ｄ−ソルボースを有効成分とする糞便脂質排泄促進用組成物 |
| US11260066B2 (en) * | 2017-10-27 | 2022-03-01 | Samyang Corporation | Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose |
| JP7216260B2 (ja) * | 2018-11-06 | 2023-02-01 | 株式会社明治 | コプロコッカス属菌の増殖促進用組成物 |
| US12318400B2 (en) | 2018-11-08 | 2025-06-03 | National University Corporation Kagawa University | Brown and beige adipocyte activating agent containing D-allulose as active ingredient |
| JP7158021B2 (ja) * | 2018-11-29 | 2022-10-21 | 松谷化学工業株式会社 | Ｃｄｃａ増加促進用組成物、ｆｘｒ増加促進用組成物及びｆｘｒ活性化促進用組成物 |
| JP6937062B2 (ja) * | 2019-02-19 | 2021-09-22 | 国立大学法人 香川大学 | 生体内機能成分を含むズイナを植物体の形態で利用する経口組成物 |
| JP7595271B2 (ja) * | 2019-02-21 | 2024-12-06 | 松谷化学工業株式会社 | 血中ｐｃｓｋ９濃度上昇抑制用組成物 |
| EP3698648A1 (en) * | 2019-02-22 | 2020-08-26 | Pfeifer & Langen GmbH & Co. KG | Allulose pet food |
| CN116963743A (zh) * | 2021-03-04 | 2023-10-27 | 庆北大学校产协力团 | 含有作为活性成分的d-核糖-2-己酮糖的用于预防、缓解或治疗肌肉疏松症的组合物 |
| KR20240108016A (ko) * | 2022-12-30 | 2024-07-09 | 주식회사 삼양사 | 알룰로스를 이용한 장 질환의 개선 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1757297B1 (en) * | 2004-05-26 | 2013-11-13 | National University Corporation Kagawa University | COMPOSITION FOR treating ARTERIOSCLEROSIS IN DIABETIC PATIENTS |
| JP5645183B2 (ja) * | 2005-07-20 | 2014-12-24 | 帝國製薬株式会社 | Ｄ−プシコースを有効成分として含む肥満状態改善剤 |
| KR20150015030A (ko) * | 2007-05-18 | 2015-02-09 | 마쓰다니가가꾸고오교가부시끼가이샤 | 슈크로오스성 감미질을 가지는 신규 감미료, 그 제조법 및 용도 |
| JP5535456B2 (ja) * | 2008-07-09 | 2014-07-02 | 松谷化学工業株式会社 | 食物繊維と希少糖を含む生体機能改善組成物。 |
| CN105188709A (zh) * | 2013-04-26 | 2015-12-23 | 松谷化学工业株式会社 | 能量消耗的促进和/或能量消耗功能降低的治疗和/或预防剂、或者方法 |
-
2015
- 2015-09-01 KR KR1020150123437A patent/KR101692033B1/ko active Active
-
2016
- 2016-09-01 UA UAA201802536A patent/UA122342C2/uk unknown
- 2016-09-01 CA CA2996872A patent/CA2996872A1/en not_active Abandoned
- 2016-09-01 WO PCT/KR2016/009812 patent/WO2017039365A1/ko not_active Ceased
- 2016-09-01 MX MX2018002507A patent/MX2018002507A/es unknown
- 2016-09-01 US US15/756,919 patent/US20180243325A1/en not_active Abandoned
- 2016-09-01 RU RU2018111327A patent/RU2725145C2/ru active
- 2016-09-01 CN CN201680050812.4A patent/CN107921052A/zh active Pending
- 2016-09-01 EP EP16842331.7A patent/EP3345608B1/en active Active
- 2016-09-01 JP JP2018530463A patent/JP6619882B2/ja active Active
- 2016-09-01 BR BR112018003842-3A patent/BR112018003842A2/pt not_active Application Discontinuation
-
2018
- 2018-02-27 CL CL2018000523A patent/CL2018000523A1/es unknown
- 2018-03-01 CO CONC2018/0002394A patent/CO2018002394A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3345608A1 (en) | 2018-07-11 |
| CA2996872A1 (en) | 2017-03-09 |
| JP2018530600A (ja) | 2018-10-18 |
| BR112018003842A2 (pt) | 2018-09-25 |
| JP6619882B2 (ja) | 2019-12-11 |
| RU2018111327A3 (es) | 2019-10-04 |
| KR101692033B1 (ko) | 2017-01-03 |
| CN107921052A (zh) | 2018-04-17 |
| RU2018111327A (ru) | 2019-10-04 |
| US20180243325A1 (en) | 2018-08-30 |
| EP3345608A4 (en) | 2019-05-01 |
| CO2018002394A2 (es) | 2018-07-19 |
| RU2725145C2 (ru) | 2020-06-30 |
| WO2017039365A1 (ko) | 2017-03-09 |
| UA122342C2 (uk) | 2020-10-26 |
| EP3345608B1 (en) | 2024-11-27 |
| CL2018000523A1 (es) | 2019-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018002507A (es) | Metodo para la inhibicion de la absorcion de lipidos y/o la promocion de excrecion de lipidos usando d-psicosa. | |
| CL2020000747A1 (es) | Formulaciones de niraparib. | |
| CL2013002210A1 (es) | Formulación prebiótica para consumo humano que comprende 2´-fucosilactosa, 3´-sialilactosa y 6´-sialilactosa, en que la cantidad en peso de 3´-sialilactosa es al menos igual de elevada que la cantidad de 2´-fucosilactosa; y método para modular o estimular la proliferación de bifidobacterias en el intestino humano. | |
| MX360554B (es) | Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2. | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| MX390627B (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| BR112015020819A2 (pt) | uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação | |
| MX384234B (es) | Uso de pridopidina para el tratamiento de enfermedad de huntington. | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| GT201300243A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
| BR112013010556A2 (pt) | métodos e composições adequadas para a promoção de uma pele saudável | |
| PE20150359A1 (es) | Manejo dietetico de la enfermedad celiaca y alergia alimentaria | |
| EA201592003A1 (ru) | Микропищевые добавки для иммунитета | |
| MX2016001635A (es) | Probiotico para el llanto infantil excesivo. | |
| BR112015013783A2 (pt) | quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses | |
| TR201821157T4 (tr) | İbandroni̇k asi̇t veya bunun farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzu ve d vi̇tami̇ni̇ i̇çeren oral uygulamaya yöneli̇k kati bi̇leşi̇m. | |
| BR112016017765A8 (pt) | composição compreendendo cinamaldeído e zinco, seu uso, e método para produzir um produto alimentício para perda de peso | |
| CO6450623A2 (es) | Parasiticidas sanguineos | |
| CY1117795T1 (el) | Φαρμακευτικες συνθεσεις απαλλαγμενες κιτρικου αλατος οι οποιες περιεχουν ανακινρα | |
| CO6602160A2 (es) | Terapia de b12 oral | |
| BR112014030288A2 (pt) | composição farmacêutica | |
| BR112016012233A8 (pt) | composições compreendendo cinamaldeído, e seus usos | |
| BR112016029749A8 (pt) | composição para perda de peso, composição que compreende cinamaldeído e zinco, seus usos, e método para fabricação de umm produto alimentício | |
| PH12016500472A1 (en) | Pidotimod for use in the treatment of inflammation-associated diseases |